Haematological malignancies, although a broad range of specific disease types, continue to show considerable overlap in classification, and patients are... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• May 2015

Functional role of CTGF in altering disease progression in a lymphoid malignancy ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2016
• September 2016

Evaluating the difference of the effects of Laryngeal mask airways compared to endotracheal tubes in older children (>1 year) in incidents of PRAE in infants. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2017
• February 2017

We provide evidence that targeting leukemia-induced bone loss is a therapeutic strategy for pre-B ALL ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2018
• November 2018

Hematopoiesis occurs in a complex bone marrow microenvironment in which bone marrow stromal cells provide critical support to the process through direct cell... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2014
• April 2014

Hannah Tom Moore Snelling HC T OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Program Head, Infection and Vaccines Head, Infectious Disease Implementation Research 08 6319 1427 08 6319 1817 Hannah.moore@telethonkids.org.au ...

• 1. Telethon Kids Institute
• Projects

The prognosis for high-risk childhood acute leukaemias remains dismal and established treatment protocols often cause long-term side effects in survivors. This study aims to identify more effective and safer therapeutics for these patients. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• April 2021

Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• January 2023

Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• April 2021

Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• April 2021

Ingrid Pat Laing Holt IL PG BSc PhD PhD, DSc, FRCPath, FRCPI, FAA Head, Children's Respiratory Science Emeritus Honorary Researcher 6319 1828 Ingrid.laing@telethonkids.org.au@hotmail.cmo Patrick.Holt@telethonkids.org.au Honorary Research Fellow ...

• 1. Telethon Kids Institute
• Projects

Identified romidepsin as a promising therapeutic for mixed lineage leukemia (MLL)-rearranged infant acute lymphoblastic leukemia ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2017
• January 2017